Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.marketscreener.com/CYTOSORBENTS-CORPORATION-19475884/news/CYTOSORBENTS-CORP-Other-Events-form-8-K-30968516/
07/22/2020 | 06:03am EDT
Item 8.01 Other Events
On July 21, 2020, the CytoSorbents Corporation (the "Company") received notification that it received a U.S. Army Medical Research Acquisition Activity Award (the "USAMRAAA") for its HemoDefend™ platform, a development-stage technology designed to be a practical, low cost, and effective way to safeguard the quality and safety of the blood supply. The USAMRAAA award, for up to $4,421,487.00, was granted to the Company in order to develop a highly efficient adsorber to remove anti-A and Anti-B antibodies from blood and plasma for transfusion. This Award is supported by the U.S. Department of Defense Peer Reviewed Medical Research Program (PRMRP)/Congressionally Directed Medical Research Program (CDMRP) under Contract No. W81XWH2010712. HemoDefend is not yet approved in the U.S. or elsewhere.
Couple of thoughts, Covid-19 will still be here into 2021 or until there is a vaccine, so I don't agree that sales will drop in Q3 or Q4. Second thought, Cytosorbent's wouldn't be looking to scale up manufacturing if they believed sales were going to drop into the single digits. Based on this I think your numbers are way too low.
You think this is going to go away when it warms up? LOL
Do you think Fresenius will act as the main distributor for Cytosorb in the US in the near term, under the EUA?
Finally, 11 years long, MSBT days, penny stock, thank you Dr Chan!
I do think he is talking about Cytosorb, Dr Claudio Ronco is an advisor to Cytosorbents.
Barda - Joint Covid-19 task force - Absolutely in there! expect update soon.
In collaboration with FDA for compassionate use in the US
More than 40 requests for emergency use in the US
I believe we are still in the remaining 15 products. Here is what Dr Chan said in the latest press release, why would he say this if they weren't still working on it.
That said, within the past week, we have received many unsolicited requests for emergency use from hospitals all over the country and are in discussions with the FDA on how to streamline this process, enable access of the CytoSorb technology to as many U.S. hospitals in the least burdensome way possible, treat patients earlier in the disease progression to have the best chance of success, and to collect patient-level data that can be used to optimize treatment for future patients and potentially support fast-track regulatory status. Meanwhile, we continue to update BARDA and the U.S. Joint COVID-19 Task Force with our progress. We seek support to scale our manufacturing, to subsidize our efforts to provide CytoSorb to hospitals for emergency use, and to help fund a clinical study in COVID-19 patients.”
According to FDA, there are 10 therapeutic agents in active clinical trials and another 15 products still in planning stages, although the specific products and companies are not mentioned due to commercial confidentiality issues.
However, FDA says it will update the page with summary statistics “to the extent permitted by confidentiality laws,” and link to public information regarding clinical trials and products in preclinical development.
With the rapid increase in the number of cases in Italy (105 currently in ICU) there is a good chance Cytosorb has already been used.
https://www.aferetica.com/possibile-uso-di-cytosorb-in-pazienti-affetti-da-covid-19/
From the Press Release on 1/28/2020
These data provide the rationale to potentially use CytoSorb, the first specifically-approved extracorporeal cytokine adsorber in the European Union, in this setting. CytoSorb is distributed in 58 countries worldwide, and is available in Hong Kong, Vietnam, Malaysia, France, and Australia where patients infected with the virus have been reported.
Pamela Youde Nethersole Eastern Hospital
I believe this might be one of the hospitals in Hong Kong that might be using Cytosorb. They claim to be one of five hospitals in Hong Kong to offer ECMO, remember Cytosorbents offers a ECMO kit. They are treating covid-19 patients and Cytosorb is available in Hong Kong.
https://www.scmp.com/news/hong-kong/health-environment/article/3050848/coronavirus-man-middle-class-hong-kong
http://www.ha.org.hk/pyneh/internet/Eng/scope/ICU/DOC/ICU.pdf
Cytosorbents has been added to wikipedia under Therapy
https://en.wikipedia.org/wiki/2019-nCoV_acute_respiratory_disease
I wish they would have mentioned Cytosorb
https://focustaiwan.tw/sci-tech/202002090008
Just curious, who has bought more shares recently?
I personally have purchased 2,000 more shares in the past month or so, at $3.70, $4.00 and $4.30 for an average of $4.00. Holding over 15,000 shares...been here since March of 2009...MSBT days...never sold a share. Family and friends hold another 50,000 shares easily. IMO we may be reaching the inflection point Dr Chan talked about years ago...2019-nCoV...I hate to profit off others misfortunes but...
Medical Device News Magazine article
https://infomeddnews.com/cytosorb-the-wuhan-coronavirus-and-cytokine-storm/
The big deal here is "standard of care", everyone that has this procedure will now be given Cytosorb as stand of care.
Mr. Capponi concluded, "Now that we can officially market this application on-label internationally, we plan to drive CytoSorb as standard of care for the removal of ticagrelor during cardiopulmonary bypass procedures in every country we serve, supported by additional studies in the U.K and elsewhere. In addition, we are aggressively pursuing an approval path for this application in the United States as well."
You can email Dr Chan at pchan@cytosorbents.com
I have been emailing him for years, sometimes he responds, sometimes he doesn't.
FDA approval within the next 7 months? Do you really think this is possible?
In regards to Kymriah approval, this is from Q3 2017
We have had a lot of success in treating secondary HLH, which is why we feel very confident that CytoSorb could help treat cytokine release syndrome in CAR-T Cell immunotherapy patients. We envision that CytoSorb can be used after tocilizumab, which is typically first line therapy to treat cytokine release syndrome, but before steroids which has been reported to be used on three quarters of the patients who get severe CRS. The problem with steroids is that it can kill or damage the very expensive CAR-T immunotherapy that costs between $300,000 to $500,000 per treatment. That would obviously be a bad thing.
In terms of usage in Europe, we benefit from the fact that we have had this clinical experience in HLH and are approved to treat cytokine release syndrome and cytokine storm in Europe and other countries where we are selling CytoSorb such as Russia, India, Vietnam, and many other countries. We think that once the approvals for Kymriah and Yescarta spread abroad, we will likely get some fairly rapid usage, particularly in Germany where we have a very strong footprint among most of the major hospitals that would be doing this type of therapy.
Not to pressure you but I can't believe you haven't calculated the share price, I have followed you for years and know that you have made lots of money off CTSO "chateau CTSO" so again without too much pressure, what is your estimate?
dah, you are a retired wall street guy, based on the new information today, 80 million in sales within 3-5 years, what is your projection of share price in 3-5 years?
Earnings out on August 2nd, Cytosorbents to my recollection has never released earnings early, good things to come. GLTA
2017 Q4 revenues were announced already at between (4.5 - 4.7) million.
Q1 2018 earnings will be on or around May 10th.
This question is the same one I had to answer with ISRG, bought in at $15 sold at $100. I will not make that same mistake again.
Acute Kidney Injury
According to Cytosorbents Corporation's most recent Form 4 filing with the SEC dated Dec 07 05:25 PM, company Chief Financial Officer, Bloch Kathleen P. disclosed buying 1,000 shares at a cost of $4.83. At the time of this transaction (Dec 06), this trade was worth $4,829 in total. As of Dec 06, Bloch Kathleen P. now owns 8,000 shares in total worth about $41,600.0.
It is all in anticipation of what Dr John Kellum says at the conference. He is the sepsis guru and when he comes out and endorses Cytosorb people are going to listen, almost as good as getting FDA approval.
Age of Transfused Blood in critically ill adults.
http://www.nejm.org/doi/full/10.1056/NEJMoa1500704#t=articleTop
I am figuring $1,600,000 for Q4 and $2,500,000 for Q1 2015. This based off similar growth rates of 55% Q over Q.
(3) new job openings at Biocon to sell Cytosorb.
http://jobsearch.naukri.com/job-listings-Key-Account-Manager-Pharma-Sales-Biocon-Limited-Hyderabad-Secunderabad-Delhi-Pune-2-to-3-years-090215000214
When do you expect the shareholder letter?
Per facebook the quiet period has ended.